Week 9 semaglutide expectations: what the data shows

What did @thatmomfriendd actually say?

She's been on semaglutide for nine weeks and has "lost and gained the same four pounds" the whole time. She's frustrated, working out twice a week, eating relatively clean on weekdays, and expected to have lost around 20 pounds by now. She also mentioned the concept of "super responders" versus slower responders, noted that friends told her results kicked in around the three-month mark, and admitted she accidentally stayed at 20 units instead of moving up to 30 units this week.

She's not making wild claims. She's not selling anything. She's documenting a genuinely common experience and trying to make sense of why the medication isn't working the way she anticipated. That honesty is worth acknowledging before we get into what the evidence actually says.

Does the science back this up?

Yes, mostly. Slow initial response to semaglutide is well-documented, and the "super responder" framing, while not a formal clinical term, reflects real variability in outcomes seen in trials.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed an average weight loss of about 14.9% body weight over 68 weeks at the full 2.4 mg weekly dose of semaglutide. But that's an average across thousands of participants. A subset lost significantly more; others lost much less. The trial also used a slow titration schedule, ramping up over 16 weeks before hitting the full dose. Expecting 20 pounds in nine weeks, especially while still titrating, is not aligned with how the drug actually works in studies.

Her friends' advice about the three-month mark is consistent with clinical timelines too. Davies et al. (2021, Diabetes Care) noted that meaningful weight loss with GLP-1 agonists typically becomes more apparent once patients reach or approach their maintenance dose, which for most titration schedules takes 12 to 16 weeks to reach.

What did they get wrong (or right)?

She got more right than wrong, but her expectations were off, and that matters for how people interpret their own results.

The idea that people "not exercising, eating like literal crap" are losing weight fast is partially true but incomplete. Early weight loss on semaglutide is heavily driven by appetite suppression, reduced caloric intake, and in some cases, water weight and reduced inflammation. Someone eating poorly but eating far less may drop weight faster initially. That doesn't mean they're healthier or that her approach is wrong. Eating cleaner with moderate exercise is the more sustainable combination according to the STEP 5 trial (Garvey et al., 2022, Nature Medicine), which showed that lifestyle intervention alongside the medication produced better long-term outcomes than medication alone.

Her math confusion about dosing units is concerning from a safety standpoint, not because she did anything dangerous, but because unit-based dosing language varies significantly depending on the device, concentration, and formulation being used. Anyone on a titration schedule should be confirming dose changes directly with their prescriber, not recalculating independently.

What should you actually know?

Nine weeks on a titration schedule is still early, especially if you haven't reached your target dose yet. That part of her story is genuinely under-discussed in GLP-1 content online.

The SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM) with liraglutide and the subsequent STEP program data both show that weight loss with GLP-1 receptor agonists accelerates after reaching the maintenance dose and continues for months. Comparing your week 9 results to someone else's week 20 results is not a fair comparison, and a lot of the viral before-and-after content doesn't specify where in the titration process those results occurred.

Two workouts a week is genuinely low if weight loss is the goal. The American College of Sports Medicine recommends 150 to 250 minutes of moderate activity per week for meaningful weight loss. That said, GLP-1 medications work independently of exercise. Exercise matters more for preserving lean muscle mass during weight loss, which is a real concern with rapid semaglutide-driven fat loss, as noted by Bikou et al. (2023, Obesity Reviews).

• Slow response at week 9 is common, not a sign the medication is failing.
• The "super responder" concept reflects real variability but is not a defined clinical category.
• Dose titration timing directly affects how quickly results appear.
• Exercise during GLP-1 treatment helps preserve muscle, not just accelerate fat loss.

Bottom line

She's not spreading misinformation. She's sharing a frustrating but medically normal experience and framing it honestly. The expectation of 20 pounds in nine weeks is the main thing worth pushing back on. That figure is not supported by the clinical trial timeline for this drug class. If you're in a similar position, the evidence suggests staying on the titration schedule, talking to your provider before adjusting doses, and not benchmarking your progress against people who are further along or responding atypically fast.